BioXcel Therapeutics is trading 5.6% down at $0.11 after declining from the September 3, 2026 regular-session close of $0.12, amid overhang from the company’s Chapter 11 filing.
- No new company-specific announcement was identified for September 3.
- Nasdaq’s decision to suspend trading on September 8, 2026, remains a significant investor overhang.
- The broader biotech rebound did not explain the after-hours decline; confidence is low without a direct catalyst.